Literature DB >> 15994236

The structural basis of androgen receptor activation: intramolecular and intermolecular amino-carboxy interactions.

Fred Schaufele1, Xavier Carbonell, Martin Guerbadot, Sabine Borngraeber, Mark S Chapman, Aye Aye K Ma, Jeffrey N Miner, Marc I Diamond.   

Abstract

Nuclear receptors (NRs) are ligand-regulated transcription factors important in human physiology and disease. In certain NRs, including the androgen receptor (AR), ligand binding to the carboxy-terminal domain (LBD) regulates transcriptional activation functions in the LBD and amino-terminal domain (NTD). The basis for NTD-LBD communication is unknown but may involve NTD-LBD interactions either within a single receptor or between different members of an AR dimer. Here, measurement of FRET between fluorophores attached to the NTD and LBD of the AR established that agonist binding initiated an intramolecular NTD-LBD interaction in the nucleus and cytoplasm. This intramolecular folding was followed by AR self-association, which occurred preferentially in the nucleus. Rapid, ligand-induced intramolecular folding and delayed association also were observed for estrogen receptor-alpha but not for peroxisome proliferator activated receptor-gamma2. An antagonist ligand, hydroxyflutamide, blocked the NTD-LBD association within AR. NTD-LBD association also closely correlated with the transcriptional activation by heterologous ligands of AR mutants isolated from hormone-refractory prostate tumors. Intramolecular folding, but not AR-AR affinity, was disrupted by mutation of an alpha-helical ((23)FQNLF(27)) motif in the AR NTD previously described to interact with the AR LBD in vitro. This work establishes an intramolecular NTD-LBD conformational change as an initial component of ligand-regulated NR function.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15994236      PMCID: PMC1168953          DOI: 10.1073/pnas.0408819102

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  34 in total

1.  Activation function 2 in the human androgen receptor ligand binding domain mediates interdomain communication with the NH(2)-terminal domain.

Authors:  B He; J A Kemppainen; J J Voegel; H Gronemeyer; E M Wilson
Journal:  J Biol Chem       Date:  1999-12-24       Impact factor: 5.157

Review 2.  Combinatorial control of gene expression by nuclear receptors and coregulators.

Authors:  Neil J McKenna; Bert W O'Malley
Journal:  Cell       Date:  2002-02-22       Impact factor: 41.582

3.  Dependence of selective gene activation on the androgen receptor NH2- and COOH-terminal interaction.

Authors:  Bin He; Lori W Lee; John T Minges; Elizabeth M Wilson
Journal:  J Biol Chem       Date:  2002-05-08       Impact factor: 5.157

Review 4.  Creating new fluorescent probes for cell biology.

Authors:  Jin Zhang; Robert E Campbell; Alice Y Ting; Roger Y Tsien
Journal:  Nat Rev Mol Cell Biol       Date:  2002-12       Impact factor: 94.444

5.  Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone.

Authors:  J S Sack; K F Kish; C Wang; R M Attar; S E Kiefer; Y An; G Y Wu; J E Scheffler; M E Salvati; S R Krystek; R Weinmann; H M Einspahr
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-24       Impact factor: 11.205

6.  Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen.

Authors:  C W Gregory; R T Johnson; J L Mohler; F S French; E M Wilson
Journal:  Cancer Res       Date:  2001-04-01       Impact factor: 12.701

7.  FXXLF and WXXLF sequences mediate the NH2-terminal interaction with the ligand binding domain of the androgen receptor.

Authors:  B He; J A Kemppainen; E M Wilson
Journal:  J Biol Chem       Date:  2000-07-28       Impact factor: 5.157

8.  Structural basis for the glucocorticoid response in a mutant human androgen receptor (AR(ccr)) derived from an androgen-independent prostate cancer.

Authors:  Pedro M Matias; Maria Arménia Carrondo; Ricardo Coelho; Monica Thomaz; Xiao-Yan Zhao; Anja Wegg; Kerstin Crusius; Ursula Egner; Peter Donner
Journal:  J Med Chem       Date:  2002-03-28       Impact factor: 7.446

9.  Ligand-selective interactions of ER detected in living cells by fluorescence resonance energy transfer.

Authors:  R V Weatherman; C-Y Chang; N J Clegg; D C Carroll; R N Day; J D Baxter; D P McDonnell; T S Scanlan; F Schaufele
Journal:  Mol Endocrinol       Date:  2002-03

10.  Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.

Authors:  M Baum; A U Budzar; J Cuzick; J Forbes; J H Houghton; J G M Klijn; T Sahmoud
Journal:  Lancet       Date:  2002-06-22       Impact factor: 79.321

View more
  70 in total

Review 1.  Small molecule inhibitors as probes for estrogen and androgen receptor action.

Authors:  David J Shapiro; Chengjian Mao; Milu T Cherian
Journal:  J Biol Chem       Date:  2010-12-13       Impact factor: 5.157

2.  Evidence for DNA-binding domain--ligand-binding domain communications in the androgen receptor.

Authors:  Christine Helsen; Vanessa Dubois; Annelien Verfaillie; Jacques Young; Mieke Trekels; Renée Vancraenenbroeck; Marc De Maeyer; Frank Claessens
Journal:  Mol Cell Biol       Date:  2012-05-29       Impact factor: 4.272

3.  Muscle-bound? A tissue-selective nonsteroidal androgen receptor modulator.

Authors:  Elizabeth M Wilson
Journal:  Endocrinology       Date:  2007-01       Impact factor: 4.736

4.  Androgen receptor decoy molecules block the growth of prostate cancer.

Authors:  Steven N Quayle; Nasrin R Mawji; Jun Wang; Marianne D Sadar
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-16       Impact factor: 11.205

5.  Proteomic analyses to identify novel therapeutic targets for the treatment of advanced prostate cancer.

Authors:  Barbara Comuzzi; Marianne D Sadar
Journal:  Cellscience       Date:  2006-07-27

6.  SUMOylation of pontin chromatin-remodeling complex reveals a signal integration code in prostate cancer cells.

Authors:  Jung Hwa Kim; Ji Min Lee; Hye Jin Nam; Hee June Choi; Jung Woo Yang; Jason S Lee; Mi Hyang Kim; Su-Il Kim; Chin Ha Chung; Keun Il Kim; Sung Hee Baek
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-17       Impact factor: 11.205

7.  Intermolecular interactions between retroviral Gag proteins in the nucleus.

Authors:  Scott P Kenney; Timothy L Lochmann; Cullen L Schmid; Leslie J Parent
Journal:  J Virol       Date:  2007-10-31       Impact factor: 5.103

Review 8.  Targeting apoptosis pathway with natural terpenoids: implications for treatment of breast and prostate cancer.

Authors:  Huanjie Yang; Q Ping Dou
Journal:  Curr Drug Targets       Date:  2010-06       Impact factor: 3.465

9.  AR inhibitors identified by high-throughput microscopy detection of conformational change and subcellular localization.

Authors:  Jeremy O Jones; W Frank An; Marc I Diamond
Journal:  ACS Chem Biol       Date:  2009-03-20       Impact factor: 5.100

10.  Increased expression of EphA1 protein in prostate cancers correlates with high Gleason score.

Authors:  Libo Peng; Haiyan Wang; Yingchun Dong; Jie Ma; Juanjuan Wen; Jinrong Wu; Xueqing Wang; Xiaojun Zhou; Jiandong Wang
Journal:  Int J Clin Exp Pathol       Date:  2013-08-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.